The drug, gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's endocrine therapy Faslodex, reduced the risk of ...

Baxdrostat is a highly selective, second-generation, nonimidazole aldosterone synthase inhibitor; 100 times less baxdrostat ...

During Brazil's COVID-19 vaccination campaign, when several brands of vaccines were available and the Chinese vaccine was the ...

During Brazil's COVID-19 vaccination campaign, when several brands of vaccines were available and the Chinese vaccine was the ...

Celcuity shares soar 186% after Phase 3 breast cancer trial shows triple therapy delays disease by over 7 months.

AIM ImmunoTech shares climbed after the company reported positive data from a Phase 2 study evaluating treatment of metastatic pancreatic cancer patients with stable disease after a combination ...

Shares of AstraZeneca were trading at $72.66 as of July 25. Over the last 52-week period, shares are down 7.46%. Given that these returns are generally negative, long-term shareholders are likely ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

Antibody-drug conjugates are a growing class of biopharmaceuticals that combine the precision of monoclonal antibodies with ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...